Lukas Kraehenbuehl

1.6k total citations · 1 hit paper
23 papers, 762 citations indexed

About

Lukas Kraehenbuehl is a scholar working on Oncology, Dermatology and Immunology. According to data from OpenAlex, Lukas Kraehenbuehl has authored 23 papers receiving a total of 762 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 6 papers in Dermatology and 5 papers in Immunology. Recurrent topics in Lukas Kraehenbuehl's work include Cancer Immunotherapy and Biomarkers (15 papers), CAR-T cell therapy research (4 papers) and Drug-Induced Adverse Reactions (4 papers). Lukas Kraehenbuehl is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), CAR-T cell therapy research (4 papers) and Drug-Induced Adverse Reactions (4 papers). Lukas Kraehenbuehl collaborates with scholars based in United States, Switzerland and Greece. Lukas Kraehenbuehl's co-authors include Taha Merghoub, Jedd D. Wolchok, Chien‐Huan Weng, Shabnam Eghbali, Mario E. Lacouture, Donald Y.M. Leung, Jeffrey A. Kern, Elena Goleva, Taras Lyubchenko and Arved Weimann and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Lukas Kraehenbuehl

17 papers receiving 752 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

2021 557 citations Lukas Kraehenbuehl, Chien‐Huan Weng et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lukas Kraehenbuehl United States	9	452	327	190	132	96	23	762
Pushpamali De Silva Belgium	21	708 1.6×	478 1.5×	211 1.1×	286 2.2×	140 1.5×	36	1.1k
Takanori Maruyama Japan	15	495 1.1×	474 1.4×	120 0.6×	113 0.9×	28 0.3×	24	856
Lucia D’Amico Italy	17	403 0.9×	178 0.5×	335 1.8×	123 0.9×	27 0.3×	24	755
Kristelle J. Capistrano United States	9	315 0.7×	468 1.4×	352 1.9×	75 0.6×	61 0.6×	16	931
Robert Saddawi‐Konefka United States	13	299 0.7×	431 1.3×	207 1.1×	83 0.6×	31 0.3×	32	774
Christopher M. Sheth United States	9	194 0.4×	160 0.5×	306 1.6×	36 0.3×	96 1.0×	11	791
Xinsheng Xie China	15	171 0.4×	167 0.5×	370 1.9×	99 0.8×	29 0.3×	72	726
Li Ren China	14	250 0.6×	158 0.5×	172 0.9×	129 1.0×	20 0.2×	31	610
Jochen T. Schaefer United States	11	480 1.1×	430 1.3×	151 0.8×	81 0.6×	22 0.2×	17	802
Guanqun Li China	18	248 0.5×	110 0.3×	410 2.2×	124 0.9×	42 0.4×	51	860

Countries citing papers authored by Lukas Kraehenbuehl

Since Specialization

Citations

This map shows the geographic impact of Lukas Kraehenbuehl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lukas Kraehenbuehl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lukas Kraehenbuehl more than expected).

Fields of papers citing papers by Lukas Kraehenbuehl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lukas Kraehenbuehl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lukas Kraehenbuehl. The network helps show where Lukas Kraehenbuehl may publish in the future.

Co-authorship network of co-authors of Lukas Kraehenbuehl

This figure shows the co-authorship network connecting the top 25 collaborators of Lukas Kraehenbuehl. A scholar is included among the top collaborators of Lukas Kraehenbuehl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lukas Kraehenbuehl. Lukas Kraehenbuehl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kraehenbuehl, Lukas, et al.. (2026). Racial and Ethnic Disparities in Persistent Chemotherapy-Induced Alopecia Among Women With Breast Cancer. JAMA Network Open. 9(1). e2549146–e2549146.

Kraehenbuehl, Lukas, Patrick Turko, Adhideb Ghosh, et al.. (2025). Immune-Related Cutaneous Adverse Events Display Distinct Clinical and Molecular Characteristics, Depending on Immune Checkpoints Targeted. Cancers. 17(12). 1992–1992.

Gómez, Julia M. Martínez, Patrick Turko, Egle Ramelyte, et al.. (2024). Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland. Cancers. 16(5). 854–854. 2 indexed citations

Lacouture, Mario E., Elena Goleva, Neil J. Shah, et al.. (2024). Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways. Clinical Cancer Research. 30(13). 2822–2834. 13 indexed citations

Reingold, Rachel, Alexander Pan, Lukas Kraehenbuehl, et al.. (2024). Oral minoxidil for late alopecia in cancer survivors. Breast Cancer Research and Treatment. 208(3). 491–499. 8 indexed citations

Goleva, Elena, Mario E. Lacouture, Taras Lyubchenko, et al.. (2024). Checkpoint inhibitor-related skin reactions in cancer patients are characterized by unique rash specific immune responses. Journal of Allergy and Clinical Immunology. 153(2). AB227–AB227.

Guen, Emilie Le, Reinhard Dummer, Dorothee Gramatzki, et al.. (2024). IMUN-03 IT-IO: INTRATHECAL ADMINISTRATION OF NIVOLUMAB AND IPILIMUMAB IN COMBINATION WITH SYSTEMIC COMBINATION OF NIVOLUMAB AND IPILIMUMAB IN PATIENTS WITH NSCLC OR MELANOMA AND NEWLY DIAGNOSED LEPTOMENINGEAL METASTASIS, A MULTICENTRIC PHASE I STUDY - PRELIMINARY DATA. Neuro-Oncology Advances. 6(Supplement_1). i14–i14. 1 indexed citations

Moy, Andrea P., Stephen W. Dusza, Yelena Y. Janjigian, et al.. (2023). Management of immune-related cutaneous adverse events with dupilumab. Journal for ImmunoTherapy of Cancer. 11(6). e007324–e007324. 25 indexed citations

Kraehenbuehl, Lukas, Stephanie Schneider, Joanna Mangana, et al.. (2023). Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis. Pharmaceuticals. 16(7). 935–935.

10.

Kraehenbuehl, Lukas, Aliya Holland, Levi Mangarin, et al.. (2022). Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers. 14(11). 2638–2638. 15 indexed citations

11.

Wang, Evelyn N., Taras Lyubchenko, Elena Goleva, et al.. (2022). Checkpoint inhibition induced pruritus during cancer therapy is associated with skin IL-31 and CCL22 expression. Journal of Allergy and Clinical Immunology. 149(2). AB173–AB173. 2 indexed citations

12.

Goleva, Elena, et al.. (2022). Effect of immune checkpoint inhibitors on asthma. Annals of Allergy Asthma & Immunology. 129(2). 257–258. 1 indexed citations

13.

Kraehenbuehl, Lukas, Stephanie King, Donald Y.M. Leung, et al.. (2022). Contribution of the Skin–Gut Axis to Immune-Related Adverse Events with Multi-System Involvement. Cancers. 14(12). 2995–2995. 7 indexed citations

14.

Goleva, Elena, Taras Lyubchenko, Lukas Kraehenbuehl, et al.. (2021). Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Annals of Allergy Asthma & Immunology. 126(6). 630–638. 31 indexed citations

15.

Apalla, Zoé, Vasiliki Nikolaou, Davide Fattore, et al.. (2021). European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement. Journal of the European Academy of Dermatology and Venereology. 36(3). 332–350. 46 indexed citations

16.

Wang, Evelyn N., et al.. (2021). Immune-related cutaneous adverse events due to checkpoint inhibitors. Annals of Allergy Asthma & Immunology. 126(6). 613–622. 19 indexed citations

17.

Kraehenbuehl, Lukas, Chien‐Huan Weng, Shabnam Eghbali, Jedd D. Wolchok, & Taha Merghoub. (2021). Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nature Reviews Clinical Oncology. 19(1). 37–50. 557 indexed citations breakdown →

18.

Weimann, Arved, Stefan Holland‐Cunz, K.‐W. Jauch, et al.. (2009). Surgery and transplantation – Guidelines on Parenteral Nutrition, Chapter 18. SHILAP Revista de lepidopterología. 7. Doc10–Doc10. 10 indexed citations

19.

Hoogewoud, H. M., et al.. (2008). Enhanced Tumour Growth and Impaired Cellular Antitumoural Defence in Hepatic Colorectal Carcinoma Metastasis in Rats after Laparoscopy Compared to Open Surgery. Annals of Surgical Oncology. 15(4). 1239–1248.

20.

Windsor, Alastair, Marco Braga, Robert G. Martindale, et al.. (2004). Fit for surgery: An expert panel review on optimising patients prior to surgery, with a particular focus on nutrition. The Surgeon. 2(6). 315–319. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact